Home › Acute Biphenotypic Leukemia › New Hampshire
Acute Biphenotypic Leukemia clinical trials in New Hampshire
3 studies for Acute Biphenotypic Leukemia are looking for participants at sites in New Hampshire.
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
RecruitingPhase 2
365 Days · All sexes · Updated Sep 25, 2026 · NCT06317662Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
RecruitingPhase 3
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.